Other
DME
0
Pipeline Programs↗
3
Active Trials↗
10
Companies Involved↗
DME is an early-stage landscape with 0 programs across 10 companies. The most active players are AstraZeneca, Sunshine Lake Pharma Co., Ltd., Tillotts Pharma AG.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
37
clinical trials
Completed32 · 86%
Not yet recruiting2 · 5%
Active, not recruiting1 · 3%
Unknown status1 · 3%
Withdrawn1 · 3%
Clinical Trials
Trial Activity
37 trials
Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.
Completed·—·Phase 2·NCT02571972·14 enrolled
Human Genomic Population Structure and Phenotype-genotype Variation in ADME Genes in Four Populations
Completed·—·N/A·NCT02789527·367 enrolled
Variable Interval Versus Set Interval Aflibercept for DME
Completed·—·Phase 4·NCT02392364·50 enrolled
Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO
Completed·—·Phase 4·NCT02503540·31 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)